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Abstract
Background: Introduction of Xpert® MTB/RIF assay has revolutionalised the diagnosis of tuberculosis (TB) by
simultaneously detecting the bacteria and resistance to rifampicin (rif), a surrogate marker for multi-drug
resistant TB (MDR-TB) as well as one of the principal first-line anti-tuberculosis drugs. In general, rpoB mutations can
be found in 96.1% of rif-resistant Mycobacterium tuberculosis (MTB) strains worldwide and these mutations usually are
located in a region at the 507-533rd amino acid residuals (81 bp) in the MTB rpoB gene, which is referred to as
Rifampicin-resistance-determining region (RRDR). In this study, we determined the frequency of MDR-TB in Kampala
using Xpert® MTB/RIF in comparison with the agar proportion method using Middlebrook 7H11and further determined
the frequency of probes for different rpoB gene mutations using Xpert® MTB/RIF assay in the 81 bp RRDR.
Methods: A total of 1501 specimens received at Mycobacteriology laboratory, Makerere University for Xpert testing
between May 2011 and May 2014 were analysed by Xpert® MTB/RIF assay. Specimens that were positive for both MTB
and rifampicin resistance were further subjected to a complete first line anti-mycobacterial drug susceptibility testing
using Middlebrook 7H11 agar proportion method (APM).
Results: Xpert® MTB/RIF assay detected 313 MTB positive specimens and out of which 12 specimens had both MTB
and rifampicin- resistance conferred by four different rpoB gene mutations in the 81 bp-RRDR of MTB, further one
(1/12), specimen was found to be rifampicin mono-resistant on APM while the 11 were found to be MDR-TB. Probes
associated with the observed rif- resistance were as follows: E (7/12), B (3/12), A (1/12), D (1/12) and no rif-resistance
was associated with probe C. No specimen yielded rif-resistance associated with more than one probe failure (mutation
combinations). Probe D was associated with rifampicin mono-resistant.
Conclusions: MDR-TB was at 3.5% in the studied population. Mutations associated with Probe E (58%) also known as
codons 531and 533 are the commonest rpoB gene mutation identified by Xpert® MTB/RIF assay in this setting and
mutations identified by probe E of the assay, turned out to be MDR-TB strains by agar proportion method
antimicrobial susceptibility testing. No mutation was detected in the codon 522.
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Background
Introduction of Xpert® MTB/RIF assay (Cepheid, USA)
has revolutionalised the diagnosis of tuberculosis (TB)
by simultaneously detecting the bacteria and resistance
to rifampicin (rif ) [1,2], one of the principal first-line
anti-tuberculosis drugs, which inhibits DNA-directed
RNA synthesis of Mycobacterium tuberculosis (MTB) pro-
teins by binding to the β-subunit of bacterial DNA
dependent RNA polymerase (rpoB) enzyme. In general,
rpoB mutations can be found in 96.1% of rif-resistant
MTB strains worldwide and these mutations are usually
located in a region at the 507- 533th amino acid residuals
(81 bp) in the rpoB gene, which is often called rifampicin-
resistance determining region (RRDR) [3]. Rifampicin re-
sistance is a valuable surrogate marker of multi drug re-
sistant (MDR) TB [4].
Uganda ranked 16th among 22 high TB burden nations
and WHO, 2012 report showed that the prevalence of
MDR-TB was 1.4% and 12% among new and previously
treated TB cases, respectively. In Uganda, a total of 1406
cases tested for MDR-TB with 89 laboratory confirmed
cases and only 41 cases were started on treatment [5].
The biological features of bacteria, including drug resist-
ance; usually differ in diverse geographical regions [6-10].
Data on prevalence of rpoB gene mutations in Uganda is
limited, therefore this study was set to provide baseline
data on these mutations using Xpert® MTB/RIF assay.
Clinical observations suggest that not only detection of
the presence but also identification of the nature of rpoB
mutation is needed for accurate diagnosis of resistance to
rifampicin [11]. Therefore, in this study; we investigated
the rif-resistant frequency of MTB strains isolated from
specimens of patients suspected to have TB in Kampala-
Uganda and the dominant site mutation types at RRDR in




The study projects referring the specimens were approved
by the Research and Ethics Committee of the School of
Biomedical Sciences of Makerere University, as well as the
Uganda National Council for Science and Technology
(UNCST). Parents/guardians were informed about the
study and written informed consent was obtained from
the parents or legal guardians, were applicable.
Clinical specimens
In total, 1501 specimens were included in the study. They
originated from patients with suspected tuberculosis infec-
tions and were sent for routine mycobacteriology diagnos-
tics between May 2011 and May 2014 at Mycobacteriology
(BSL-3) laboratory, Makerere University. This is the only
TB culture laboratory located in Mulago Hospital complex,
a national referral as well as a university teaching hospital
serving both urban and peri-urban population of about
two million people. The studies referring these specimens
had protocols approved by the School of Biomedical
Sciences ethics committee at College of Health Sciences,
Makerere University.
When these specimens were received at the laboratory,
all patient critical details were capture and specimen
characteristics (volume and consistence) were recorded
in laboratory data collection forms and later captured in
access restricted computer-based database. These speci-
mens included sputa, cerebral spinal fluid (CSF), pleural
fluid, gastric aspirate and nasopharyngeal aspirate. Tu-
berculosis diagnostic requests ranged from microscopy,
culture and Xpert® MTB/RIF assay. In addition to re-
quested routine analyses, we did perform first-line anti-TB
drug susceptibility testing on all specimens that were posi-
tive for both MTB and rif –resistance by Xpert® MTB/RIF
assay, as shown in Figure 1.
Specimens were decontaminated using N-acetyl-L-
cysteine (NALC) - sodium hydroxide (NaOH) except
cerebral spinal fluid (CSF). After concentration by cen-
trifugation at 3000 g for 15 minutes, the sediment was
resuspended in 1.5 ml of 0.5 M phosphate buffer (pH 6.8)
and inoculated in MGIT-7H9 broth supplemented with
oleic acid-albumin-dextrose-catalase (OADC) and PANTA
(Becton Dickinson). This was incubated using MGIT™
Bactec 960 instrument (Becton-Dickinson and Company,
Sparks MD) as well as Loewenstein-Jensen (LJ) medium
at 37°C. Concentrated Smears were prepared from this
suspension, stained with Auramine-O-phenol stain and vi-
sualized with a fluorescence microscope (magnification
X200 and X400). The remaining sediment was stored
frozen for other preferred tests. LJ and MGIT cultures
were incubated for up to 8 and 6 weeks respectively.
Ziehl- Neelsen (ZN) staining for acid fast bacilli was
performed on suspicious growth on LJ and MGIT™ in-
strument positive tubes. Capilia was done to confirm
MTB complex.
Agar proportion method for phenotypic drug
susceptibility testing
The agar proportion method using Middlebrook 7H11
was performed as per established standard procedures
and calculations for resistance also made as recom-
mended in standard. Mycobacterium tuberculosis H37Rv
(sensitive to all the antituberculosis agents) was used as
reference control strain. The drugs were used at critical
concentrations.
Xpert® MTB/RIF assay
Both processed sediments and unprocessed specimens
were used for the Xpert® MTB/RIF assay. This was done
according to the manufacturer’s instructions.
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Statistical methods
Test results were based on comparison of rifampicin
resistance derived from the Xpert® MTB/RIF assay using
Xpert® MTB/RIF assay G4 version 5 and Xpert® MTB/RIF
Assay G3 version 3. All the Rif-resistant-TB cases were de-
tected by Xpert® MTB/RIF G4 version 5. Results for
Xpert® MTB/RIF determined rifampicin resistance were
compared with APM results as the reference comparator
to for agreement and concordance calculated.
Results
Xpert® MTB/RIF assay: The assay detected 12 specimens
as MTB with rifampicin- resistance. The resistance was
conferred by four different rpoB gene mutations in the
81 bp-RRDR of MTB. These were detected by probes A,
B, D, and E. The probe frequency associated with the
observed rifampicin- resistance were as follows: E (7/12),
B (3/12), A (1/12), D (1/12) and no rif-resistance was as-
sociated with probe C. No specimen yielded rifampicin
resistance associated with more than one probe (mutation
combinations). Probe D was associated with rifampicin
monoresistance when compared with APM results, used
as a reference standard. Middlebrook agar Proportion
method: The APM results indicated that one (1/12),
specimen was found to be rifampicin mono-resistant
while the 11 were found to be MDR-TB. The former had
been rifampicin resistant associated with probe D.
There was concordance of 100% for rifampicin resist-
ance detection between Xpert® MTB/RIF and Middleb-
rook 7H11 APM. Xpert® MTB/RIF assay was found to
have a concordance of 91.6% for MDR-TB case detection.
The average contamination rates for MGIT and LJ
throughout the three year period was 6.5 and 3%. Out of
313 Xpert positive specimens, three patients were not re-
covered by culture (MGIT and LJ combined). They were
lost to contamination however two out of these three
specimens had smear positive results from their processed
concentrated specimens. We also report that culture had
a sensitivity that was generally better than Xpert® MTB/
RIF assay. Concentrated smear microscopy was inferior to
Xpert® MTB/RIF assay [12].
Discussion
The most common RRDR rpoB gene mutations in the
81 bp were in codons 531 (58%), 513 (25%), 526 (8%), 511
(8%), and none for codon 522. These were designated by
probes E, B, D, A, and C respectively on the Xpert® MTB/
RIF assay. A study by Yue et al. found these frequencies
Specimens processed for
Xpert   MTB/RIF (n=1501)
MTB Not detected by Xpert 
Specimens (n=1188) MTB Detected by Xpert Assay Specimens (n=313)
MTB Detected and 
Rifampicin resistance detected 
by Xpert Assay (n=12)
Isolates -Middlebrook  







Figure 1 Flow-chart of specimen analysis.
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531 (41%), 526 (40%), and 513 (4%) in China [13]. Both
studies conclude that codon 531 is the most prevalent
associated with rifampicin resistance. In the previous
studies, the sensitivity of the MTB/RIF test for detecting
rifampicin resistance was 94.4 to 100% and the specificity
was 98.3 to 100% [2,14,15]. When all the 12 rifampicin
resistant isolates by Xpert® MTB/RIF assay were subjected
to the “gold standard” agar culture-based drug suscepti-
bility testing (APM), therefore the assay had a concord-
ance of 91.6% for MDR-TB detection. No rifampicin
resistance discrepant results were observed between
Xpert® MTB/RIF and agar proportion method.
In our study, we did not identify any rifampicin resist-
ance associated with probe C; probably this particular
site of RRDR is less susceptible to mutations conferring
this resistance, though we acknowledge that our sample
size is small. However this may be explained by two pos-
sible reasons, it may mean that the selection pressure
shaping probe C associated rifampicin resistance is ab-
sent in our setting and secondly the small sample size
may have limited this likelihood. From this study, 4/12
MDR-TB (33.3%) patients said they had contacts previ-
ous with known TB patients though we could not ascer-
tain the TB status of their index cases. This therefore
puts a transmission rate of approximately 33% for these
MDR-TB strains, more in vivo studies should be done to
address the transmissibility of the MDR-TB strains.
In this study we found MDR-TB at 3.5%, WHO re-
ported of increased MDR-TB detection in 2012 in the high
TB burden countries. This was attributed to the applica-
tion of Xpert® MTB/RIF Assay [5]. Lukoye et al. reported
MDR-TB prevalence to be 1.4% and further concluded
that there was low relative prevalence of anti-TB drug re-
sistance among new patients in Uganda than what WHO
estimated [16]. Therefore the assay is a useful tool in the
global fight against TB/MDR-TB. We had about 12%
errors associated with Xpert® MTB/RIF assay diagnostic
software and Xpert® MTB/RIF Assay G3 version 3 con-
tributing more than half of the observed errors. With
the upgrade to Xpert® MTB/RIF assay G4 version 5, we
recorded a remarkable reduction in errors/invalid results
generated by the instrument.
Conclusions
In conclusion, the Xpert® MTB/RIF assay detected the
rif-resistance associated mutations in RRDR 81 bp re-
gion. Out of the 12 rif-resistant isolates detected by this
assay, 11 were MDR-TB by APM, and one was rifampicin
mono-resistant and the profile of mutations in the 81-bp
RRDR may be unique in these setting and probably can
provide baseline data for rif-resistance patterns in the
studied setting. Further studies should be done involving
many MDR-TB strains isolated from these populations
so that information about these mutations would be
useful in development of novel therapies against TB
disease. Much as the Xpert® MTB/RIF assay is user-
friendly and phenotypic anti-mycobacterial susceptibility
testing methods remain an indispensable platform for
drug susceptibility testing of MTB strains.
Further a combination of concentrated fluorescent
smear microscopy and culture still remain useful in TB
endemic settings since these provide an advantage of
detecting MTB as well as isolating the nontuberculous
mycobacteria which are gaining increasing medical im-
portance causing both pulmonary and extrapulmonary
lesions.
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